Biogen/Eisai push for second approval in Alzheimer’s disease

As well as announcing strong expectations for their newly approved drug, Biogen and Eisai are already in communications with the FDA about a pathway to approval for its follow-up, lecanemab

Reducing primary care antibiotic use may not be enough to counter antimicrobial resistance

Reducing antibiotic prescribing did not halt drug resistant E. coli infections, study found

Resilience acquires bluebird bio’s manufacturing facility as part of cell therapy alliance

The two companies plan to collaborate on the ‘next phase’ of bluebird bio's spin-off oncology cell therapy company 2seventy’s pipeline

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

COVID-19 vaccine generated $7.8bn in the second quarter of 2021 alone

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]